AzTrials
AzTrials

Coronary Artery DiseaseOPT-CADNCT01735305

Optimal Antiplatelet Therapy for Chinese Patients With Coronary Artery Disease

An observational study of Coronary Artery Disease, run by Shenyang Northern Hospital at 107 sites in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Antiplatelet therapy is the cornerstone for the prevention of atherothrombosis in patients with coronary artery disease (CAD). However, the efficacy and safety of antiplatelet therapy are varied due to ethnic and/or individual variability. Read more about this study

Who is it for?
Ages 18 to 85 years
Conditions the study is for
Coronary Artery Disease
How many people
14,032 participants
Where
107 sitesChina
Study dates
Nov 2012to Mar 2015
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patient of coronary heart disease receiving any antiplatelet therapy

Who may be able to join

  • Clinical diagnosis of coronary heart disease
  • Age >= 18 years old
  • receiving any antiplatelet agents
  • Informed written consent signed

Who cannot join

  • With severe disease and life expectancy for 6 months or less
  • Difficult to attain follow-up situations judged by researchers (travel, speech or mental disorder, etc.)
  • Taking part in an interventional clinical research

Trial locations and contacts

107 sites in 1 country.

107 sites in 1 country

China107 sites

  • Anshan central hospital

    Anshan, Liaoning

  • Anshan hospital affiliated of China Medical University

    Anshan, Liaoning

  • The first affiliated hospital of Liaoning Medical University

    Anshan, Liaoning

  • The people's hospital of Xiuyan

    Anshan, Liaoning

  • The third hospital of Anshan

    Anshan, Liaoning

  • Beijing Fuwai Hospital

    Beijin, Beijing Municipality

  • Beijing Anzhen Hospital

    Beijing, Beijing Municipality

  • Navy General Hospital

    Beijing, Beijing Municipality

  • The 304th Hospital of PLA

    Beijing, Beijing Municipality

  • The 306th of PLA

    Beijing, Beijing Municipality

  • The Luhe teaching hospital of the Capital Medical University

    Beijing, Beijing Municipality

  • The People's Hospital of Beijing University

    Beijing, Beijing Municipality

  • Yanshan hospital

    Beijing, Beijing Municipality

  • The first affiliated hospital of Bengbu Medical College

    Bengbu, Anhui

  • Central Hospital of Changchun

    Changchun, Jilin

  • The affiliated hospital to Changchun University of Chinese Medicine

    Changchun, Jilin

  • The China-Japan union hospital of Jilin University

    Changchun, Jilin

  • The First Affiliated Hospital of Jilin University

    Changchun, Jilin

  • The Second Affiliated Hospital of Jilin University

    Changchun, Jilin

  • The first hospital of Changshan

    Changshan, Hunan

  • Sichuan military general hospital

    Chengdu, Sichuan

  • Third Military Medical University Xinqiao Hospital

    Chongqing, Chongqing Municipality

  • Dalian municipal central hospital affiliated of Dalian Medical University

    Dalian, Liaoning

  • The 210th Hospital of PLA

    Dalian, Liaoning

  • Zhongshan Hospital Affiliated to Dalian University

    Dalian, Liaoning

  • The 230th of PLA

    Dandong, Liaoning

  • The people's hospital of Dandong

    Dandong, Liaoning

  • Daqing oil field hospital

    Daqing, Heilongjiang

  • Central Hospital affiliated to Shenyang Medical College

    Fengtian, Liaoning

  • Fushun central hospital

    Fushun, Liaoning

  • The 7th hospital of China Medical University

    Fushun, Liaoning

  • The Second Affiliated and gynecology and obstetirs hospital of Fuxin city

    Fuxin, Liaoning

  • The First Affiliated Hospital of Guangzhou Medical College

    Guangdong, Guangdong

  • General hospital of armed police foreces in Guangzhou

    Guangzhou, Guangdong

  • Guangdong General Hospital

    Guangzhou, Guangdong

  • Guangzhou Baiyun district hospital

    Guangzhou, Guangdong

  • Guangzhou military region general hospital

    Guangzhou, Guangdong

  • Guangzhou Panyu district central hospital

    Guangzhou, Guangdong

  • Liwan District People's Hospital of Guangzhou

    Guangzhou, Guangdong

  • The first hospital of Guangzhou

    Guangzhou, Guangdong

  • Guizhou provincial people's hospital

    Guiyang, Guizhou

  • The people's hospital of Haicheng

    Haicheng, Liaoning

  • Affiliated hospital of Hebei University of Engineering

    Handan, Hebei

  • Hangzhou first people's hospital

    Hangzhou, Zhejiang

  • Heilongjiang provincial hospital

    Harbin, Heilongjiang

  • The 211st of PLA

    Harbin, Heilongjiang

  • The People's Hospital of Hebi

    Hebi, Henan

  • The 11st of PLA

    Huiyuan, Xinjiang

  • The people's hospital of Huzhu

    Huzhu, Qinghai

  • The Affiliated Hospital of Jinggangshan University

    Ji’an, Jiangxi

  • The 222nd of PLA

    Jilin City, Jilin

  • Jinan military general hospital

    Jinan, Shandong

  • The 205th of PLA

    Jinzhou, Liaoning

  • The third affiliated hospital of Liaoning medical College

    Jinzhou, Liaoning

  • Lanzhou military region general hospital

    Lanzhou, Gansu

  • Xizang military general hospital

    Lhasa, Tibet

  • Central hospital of Liaoyang

    Liaoyang, Liaoning

  • Liaoyang Chemical General Hospital

    Liaoyang, Liaoning

  • The 201th Hospital of PLA

    Liaoyang, Liaoning

  • The 2nd people's hospital of Liaoyang

    Liaoyang, Liaoning

  • Meihekou central hospital

    Meihekou, Jilin

  • The general hospital of Xilingol League

    Mositai, Inner Mongolia

  • The first hospital of Nanjing

    Nanjing, Jiangsu

  • The 3rd people's hospital of Nanning

    Nanning, Guangxi

  • The central hospital of Nantong

    Nantong, Jiangsu

  • The 152nd Hospital of PLA

    Pingdingshan, Henan

  • Jiaozhou central hospital

    Qingdao, Shandong

  • The third affiliated hospital of Qiqihar Medical University

    Qiqihar, Heilongjiang

  • The People's Hospital of Tangxian

    Renhou, Hebei

  • The people's hospital of Rongcheng

    Rongcheng, Hebei

  • The 425th of PLA

    Sanya, Hainan

  • Eastern hospital in Shanghai

    Shanghai, Shanghai Municipality

  • Jinqiu Hospital

    Shenyang, Liaoning

  • Liaoning northern hospital

    Shenyang, Liaoning

  • Shenyang the forth hospital of people

    Shenyang, Liaoning

  • The 202nd Hospital of PLA

    Shenyang, Liaoning

  • The 242nd of PLA

    Shenyang, Liaoning

  • The 245th of PLA

    Shenyang, Liaoning

  • The 463rd Hospital of PLA

    Shenyang, Liaoning

  • The First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine

    Shenyang, Liaoning

  • The first people's hospital of Shenyang

    Shenyang, Liaoning

  • The Forth affiliated hospital of Liaoning University of Traditional Chinese Medicine

    Shenyang, Liaoning

  • The Second Affiliated Hospital of Shenyang Medical College

    Shenyang, Liaoning

  • The Third Affiliated Hospital of Shenyang Medical College

    Shenyang, Liaoning

  • Traditional Chinese Medicine hospital of Shenyang

    Shenyang, Liaoning

  • Shenzhen Longgang center hospital

    Shenzhen, Guangdong

  • Bethune International Peace Hospital

    Shijiazhuang, Hebei

  • Siping first people's hospital

    Siping, Jilin

  • Armed police foreces'hospital of Tianjin

    Tianjin, Tianjin Municipality

  • The 254th of PLA

    Tianjin, Tianjin Municipality

  • The 206th of PLA

    Tonghua, Jilin

  • The people's hospital of Tonghua

    Tonghua, Jilin

  • Tonghua central hospital

    Tonghua, Jilin

  • General hospital of Wulumuqi

    Ürümqi, Xinjiang

  • The Chest Hospital of Xinjiang Uyghur Autonomous Region

    Ürümqi, Xinjiang

  • Wuhan Asia heart hospital

    Wuhan, Hubei

  • Tangdu hospital

    Xi'an, Shaanxi

  • The 174th Hospital of PLA

    Xiamen, Fujian

  • General hospital of Ningxia Medical University

    Yinchuan, Ningxia

  • Yingkou Development Zone Hospital

    Yingkou, Liaoning

  • The 4th public hospital of Honghe

    Yisa, Yunnan

  • Yuncheng central hospital

    Yuncheng, Shanxi

  • The 251st of PLA

    Zhangjiakou, Hebei

  • The People's Hospital of Zhecheng County

    Zhecheng Chengguanzhen, Henan

  • The First Hospital of Organization Directly Under Henan Province

    Zhengzhou, Henan

  • Zhuhai people's hospital

    Zhuhai, Guangdong

  • Wanjie Hospital

    Zibo, Shandong

Other trials in China

About this study

Antiplatelet therapy is the cornerstone for the prevention of atherothrombosis in patients with coronary artery disease (CAD). However, the efficacy and safety of antiplatelet therapy are varied due to ethnic and/or individual variability. The aim of the OPT-CAD study was to demonstrate contemporary status and outcomes of antiplatelet therapy in Chinese CAD patients, and to explore predictors of ischemic or bleeding events in such cohort.Patients above 18 years old who were diagnosed as CAD and received antiplatelet therapy were prospectively enrolled in this national wide, non-intervention registry. All medications and laboratory tests were physician discretion.

Read the detailed description

Antiplatelet therapy is the cornerstone for the prevention of atherothrombosis in patients with coronary artery disease (CAD). However, the efficacy and safety of antiplatelet therapy are varied due to ethnic and/or individual variability. The aim of the OPT-CAD study was to demonstrate contemporary status and outcomes of antiplatelet therapy in Chinese CAD patients, and to explore predictors of ischemic or bleeding events in such cohort.Patients above 18 years who were diagnosed as CAD and received antiplatelet therapy were prospectively enrolled in this national wide, non-intervention registry. All medications and laboratory tests were at physician discretion.

Keywords
Coronary Artery Disease, antiplatelet therapy
Medical subject headings
Coronary Artery Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT01735305
Study groupRoleWhat they receive
Antiplatelet therapypatients with coronary artery disease receiving any antiplatelet therapy, without any intervention by the investigators.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Major adverse cardiac and cerebral events

    a composite of all cause death, myocardial infarction, stroke or any revascularization or stroke

    Measured: 12month

Secondary outcomes (8)

  1. all cause death

    Measured: 12month

  2. Stent thrombosis

    by BARC definition

    Measured: 12 month

  3. rehospitalization

    any rehospitalization for cardiac or noncardiac reasons

    Measured: 12 month

  4. any bleeding events

    by BARC definition

    Measured: 12 month

  5. recurrent angina

    Measured: 12 month

  6. myocardial infarction

    Measured: 12 months

  7. stroke

    Measured: 12 months

  8. any revascularization

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Nov 2012 (estimated)
  2. Study startNov 2012
  3. Primary completionDec 2014
  4. Study completionMar 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
14,032 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01735305
Sponsor's protocol ID
SYNH-20121113
Acronym
OPT-CAD
Status last verified
Dec 2015
First submitted
12 Nov 2012
Last updated
11 Dec 2015
Results posted
No
Data monitoring committee
Yes

Publications

  • Jiang Z, Liu H, Qiu M, Li J, Zhao W, Zhang D, Liu D, Na K, Li Y, Han Y. Long-term outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention without standard modifiable cardiovascular risk factors: findings from the OPT-CAD cohort. BMC Med. 2025 Feb 24;23(1):112. doi: 10.1186/s12916-025-03933-2.

    PubMed 39988674

  • Ma S, Jiang Z, Qiu M, Li Z, Bian L, Li Y, Han Y. Dual Antiplatelet Therapy Duration in Medically Managed Acute Coronary Syndrome Patients: Sub-Analysis of the OPT-CAD Study. Adv Ther. 2020 Jul;37(7):3150-3161. doi: 10.1007/s12325-020-01376-0. Epub 2020 May 16.

    PubMed 32418142

  • Feng YQ, He XY, Song FE, Chen JY. Association between Contrast Media Volume and 1-Year Clinical Outcomes in Patients Undergoing Coronary Angiography. Chin Med J (Engl). 2018 Oct 20;131(20):2424-2432. doi: 10.4103/0366-6999.243563.

    PubMed 30334527

Questions about this trial

What is this clinical trial studying?

An observational study of Coronary Artery Disease, run by Shenyang Northern Hospital at 107 sites in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 11 Dec 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 107 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Major adverse cardiac and cerebral events (time frame: 12month). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01735305, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Dec 2015.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in